EASD 2023 - Benefits of SGLT2 inhibitors and GLP-1 receptor agonists beyond glycaemic control @EASDiabetes
EASD 2023 - Benefits of SGLT2 inhibitors and GLP-1 receptor agonists beyond glycaemic control @EASDiabetes
Uploaded November 2023 | Updated September 2026, 3 days ago
Katherine Tuttle, André Scheen and Norbert Stefan discuss the benefits of SGLT2 inhibitors and GLP-1 receptor agonists beyond glycaemic control at EASD TV during #EASD2023. Are SGLT2 inhibitors and GLP-1 receptor agonists also beneficial for heart, kidney and liver disease?
#diabetes #cardiovasculardisease #chronickidneydisease #liverdisease
EASD 2023 - Benefits of SGLT2 inhibitors and GLP-1 receptor agonists beyond glycaemic controlEASD 2025: Harvesting the Seeds from Funding Type 1 Diabetes ResearchEASD 2025: Results from the SOUL Trial - The Diabetologists PerspectiveEASD 2024 - Identifying the Genetic Causes of Neonatal DiabetesEASD 2023 - Portrait Åke Lernmark, recipient of the Claude Bernard Prize 2023EASD 2023 - Simon Heller and Roman Hovorka looking into the future of type 1 diabetes treatmentMeet the EASD Early Career Academy - Introducing: Caterina ConteEASD 2023 - Manuela Battaglia and Florian Toti addressing the future of T1D and T2D treatmentEASD 2024: Global Numbers, Big Impact - The future of Type 1 Diabetes Screening and Care#EASD2022 Interview with Paul Franks and Robert Wagner on Precision medicine in type 2 diabetes4th EASD ECA Webinar: The EASD/ADA consensus report on the management of hyperglycaemia in T2D#EASD2022 Interview with #dedoc representatives Bastian Hauck and Renza Scibilia
European Association for the Study of Diabetes |

EASD 2023 - Benefits of SGLT2 inhibitors and GLP-1 receptor agonists beyond glycaemic control

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER